Guardant acquires MetaSight

Guardant Health, a cancer diagnostics company, has finalized the acquisition of MetaSight Diagnostics for approximately $150 million. The transaction allows Guardant to enhance its capabilities in early disease detection via next-generation liquid biopsies developed by MetaSight, targeting both chronic and acute conditions, including cancer. An initial payment of $59 million was made, with another $90 million subject to MetaSight achieving future regulatory and commercial milestones.

MetaSight, established in 2020 through a collaboration between the investment fund aMoon and the Technion-Israel Institute of Technology, adds significant value to Guardant's portfolio. This acquisition aligns with Guardant's financial projections, as the company anticipates strong revenue growth in the coming years, supported by contributions from MetaSight's technology.

Guardant's financial performance in 2025 underscored its strategic expansion plans. The firm reported a 33% year-on-year increase in total revenue, hitting $982 million. The oncology segment led this growth, seeing a 26% rise to $683.6 million. Additionally, contributions from biopharma and data offerings grew by 18%, reaching $210.1 million. The company curtailed its free cash flow burn, although operating expenses climbed to $1.07 billion, largely due to the expansion of its commercial team and increased marketing efforts.

The acquisition comes at a time when the cancer diagnostics sector is witnessing significant activity. An example is Abbott's $23 billion purchase of Exact Sciences' oncology diagnostics last year. The market is expected to grow substantially, projected by GlobalData to reach $3.1 billion by 2030. As competition intensifies, precision tools like companion diagnostics are becoming crucial to tailor therapies to individual patients, although regulatory hurdles remain a significant barrier.

Looking ahead, Guardant anticipates further revenue growth in 2026, estimating earnings between $1.25 billion and $1.28 billion, marking an increase of 27% to 30% year-on-year. Key drivers are expected to be continued expansion in its oncology segment. Analysts, including William Blair's Andrew Brackmann, point to regulatory measures, reimbursement pathways, and ongoing data generation as critical elements that will support Guardant's trajectory and enhance investor confidence.